An evaluation of ciprofloxacin pharmacokinetics in critically ill patients undergoing continuous veno-venous haemodiafiltration

BMC Clinical Pharmacology

Volumn 11, Issue , 2011, Pages

  Spooner, Almath M ^a   Deegan, Catherine ^b   D'Arcy, Deirdre M ^a   Gowing, Caitriona M ^b   Donnelly, Maria B ^b   Corrigan, Owen I ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b ADELAIDE AND MEATH HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; CREATININE; ANTIINFECTIVE AGENT;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD FLOW VELOCITY; BLOOD PUMP; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS HEMODIAFILTRATION; CREATININE CLEARANCE; CRITICALLY ILL PATIENT; DIALYSATE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SCREENING; FEMALE; FLOW RATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTENSIVE CARE UNIT; MALE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; PROSPECTIVE STUDY; ULTRAFILTRATION; UNIVERSITY HOSPITAL; BACTEREMIA; BLOOD; CRITICAL ILLNESS; HALF LIFE TIME; HEMODIAFILTRATION; INTRAVENOUS DRUG ADMINISTRATION; METABOLIC CLEARANCE RATE; METABOLISM; MIDDLE AGED;

ADULT; AGED; ANTI-BACTERIAL AGENTS; BACTEREMIA; CIPROFLOXACIN; CREATININE; CRITICAL ILLNESS; FEMALE; HALF-LIFE; HEMODIAFILTRATION; HUMANS; INFUSIONS, INTRAVENOUS; INTENSIVE CARE UNITS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 79961105471     PISSN: None     EISSN: 14726904     Source Type: Journal    
DOI: 10.1186/1472-6904-11-11     Document Type: Article

References (27)

1. Silva E, Angus DC. Epidemiology of severe sepsis. Twenty-five Years of Progress and Innovation in Intensive Care Medicine 2007, 155-162. Medizinisch Wissenschaftliche Verlag, Kuhlen R, Moreno R, Ranieri, Rhodes A.
2. Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, Moreno R, Lipman J, Gomersall C, Sakr Y, Reinhart K, . for the EPIC II Group of Investigators International Study of the Prevalence and Outcomes of Infection in Intensive Care Units. JAMA 2009, 302(21):2323-2329. 10.1001/jama.2009.1754, 19952319, for the EPIC II Group of Investigators.
3. Nseir S, Di Pompeo C, Soubrier S, Delour P, Lenci H, Roussel-Delvallez M, Onimus T, Saulnier F, Mathieu D, Durocher A. First-generation fluoroquinolones use and subsequent emergence of multiple drug resistant bacteria in the intensive care unit. Crit Care Med 2005, 33:283-289. 10.1097/01.CCM.0000152230.53473.A1, 15699829.
4. Lipman J. The new antibiotic treatment paradigm. Intensive Care Monitor 2007, 14:61-62.
5. Nierderman MS. Re-examining quinolone use in the intensive care unit; Use them right or lose the fight against resistance bacteria. Crit Care Med 2005, 33:443-444. 10.1097/01.CCM.0000153527.76103.EF, 15699851.
6. Cruciani M, Bassetti D. The fluoroquinolones as treatment for infections caused by gram-positive bacteria. J Antimicrobial Chemother 1994, 33:403-417.
7. Craig WA, Ebert S, Moffatt J. Pharmacodynamic activity of Bay y 3118 in animal infection models. Abstr 33rd Interscience conference on antimicrobial agents and chemotherapy 1993, 391.
8. Watanabe Y, Ebert S, Craig WA. AUC/MIC ratio is unifying parameter for comparison of in vivo activity among fluoroquinolones. Abst 32nd interscience conference on antimicrobial agents and chemotherapy 1992, 42.
9. Schentag JJ. The relationship between ciprofloxacin blood concentrations, MIC values, bacterial eradication and clinical outcome in patients with nosocomial pneumonia. 49-57. Ciprofloxacin iv. Defining its role in serious infection Berlin, Germany Springer-Verlag, Garrad C.
10. Scaglione F. Can PK/PD be used in everyday clinical practice?. Int J Antimicrobial Agents 2002, 19:349-353.
11. Sanchez Recio MM, Colino CI, Sanchez Navarro A. A retrospective analysis of pharmacokinetic/pharmacodynamic indices as indicators of the clinical efficacy of ciprofloxacin. J Antimicrob Chemother 2000, 45:321-328. 10.1093/jac/45.3.321, 10702551.
12. Turnidge J. Pharmacokinetics and pharmacodynamics of fluoroquinolones. Drugs 1999, 58(Suppl 2):29-36.
13. Pinder M, Bellomo R, Lipman J. Pharmacological principles of antibiotic prescription in the critically ill. Anaesth Intensive Care 2002, (30):134-44.
14. Lipman J. Towards better ICU antibiotic dosing. Crit Care Resusc 2000, (2):282-9.
15. Wallis SC, Mullany DV, Lipman J, Rickard CM, Daley PJ. Pharmacokinetics of ciprofloxacin in ICU patients on continuous veno-venous haemodiafiltration. Intensive Care Medicine 2001, 27:665-672. 10.1007/s001340100857, 11398692.
16. Bayer Healthcare Ciproxin Infusion Summary Product Characteristics. Bayer Healthcare., http://www.medicines.ie/medicine/12239/SPC/Ciproxin+Solution+for+Infusion+2mg+ml%2c+200ml/
17. MacGowan AP, White LO, Brown NM, Lovering AM, McMullin CM, Reeves DS. Serum ciprofloxacin concentrations in patients with severe sepsis being treated with ciprofloxacin 200 mg i.v. bd irrespective of renal function. J Antimicrob Chemother 1994, 33:1051-1054. 10.1093/jac/33.5.1051, 8089053.
18. Lipman J, Scribante J, Gous AG, Hon H, Tshukutsoane S, . the Baragwanath Ciprofloxacin Study Group Pharmacokinetic profiles of high- dose intravenous ciprofloxacin in severe sepsis. Antimicrob Agents Chemother 1998, 42:2235-2239. 105792, 9736541, the Baragwanath Ciprofloxacin Study Group.
19. Vancebryan K, Guay DRP, Rotschafer JC. Clinical pharmacokinetics of ciprofloxacin. Clin Pharmacokinet 1990, 19(6):434-461. 10.2165/00003088-199019060-00003, 2292168.
20. Pea F, Viale P, Pavan F, Furlanut M. Pharmacokinetic considerations for antimicrobial therapy in patients receiving renal replacement therapy. Clin Pharmacokinet 2007, 46(12):997-1038. 10.2165/00003088-200746120-00003, 18027987.
21. Bellmann R, Egger P, Bellmann-Weiler R, Joannidis M, Dunzendorfer S, Wiedermann Ch J. Pharmacokinetics of ciprofloxacin in patients with acute renal failure undergoing continuous venovenous haemofiltration: Influence of concomitant liver cirrhosis. Acta Medica Austriaca 2002, Heft 3:112-116.
22. Davis JD, Aarons L, Houston BJ. Simultaneous assay of fluoroquinolones and theophylline in plasma by high-performance liquid chromatography. Journal of Chromatography 1993, 621:105-109. 10.1016/0378-4347(93)80083-G, 8308080.
23. Hoeffken G, Lode H, Prinzing C, Borner K, Koeppe P. Pharmacokinetics of ciprofloxacin after oral and parenteral administration. Antimicrob Agents Chemother 1985, 27:375-379. 176280, 3158275.
24. Joos B, Ledergerber B, Flepp M, Bettex JD, Luthy R, Siegenthaler W. Comparison of high-pressure liquid chromatography and bioassay for determination of ciprofloxacin in serum and urine. Antimicrob Agents Chemother 1985, 27:353-356. 176276, 3158274.
25. Davies SP, Azadian BS, Kox WJ, Brown EA. Pharmacokinetics of ciprofloxacin and vancomycin in patients with acute renal failure treated by continuous haemodialysis. Nephrol Dial Transplant 1992, 7:848-54.
26. Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, Suppes R, Feinstein D, Zanotti S, Taiberg L, Gurka D, Kumar A, Cheang M. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006, 34:1589-96. 10.1097/01.CCM.0000217961.75225.E9, 16625125.
27. Malone RS, Fish DN, Abraham E, Teitelbaum I. Pharmacokinetics of Levofloxacin and Ciprofloxacin during Continuous Renal Replacement Therapy in Critically Ill Patients. Antimicrob Agents and Chemotherapy 2001, 45:2949-2954.